Answers are grounded in this paper and cite their sources.
Breast cancer is a major cause of death from cancer worldwide, with the estrogen receptor alpha (ER-α) being an important therapeutic target for hormone-dependent MCF-7 breast cancer. The goal of this study was to use an computer-aided drug design (CADD) methodology to assess 22 quinolinol analogues as potential ER-α antagonists. The CADD methodology consisted of Gaussian field-based three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis, pharmacophore modeling, a prediction of ADMET properties, molecular docking, molecular dynamics simulation (MD), and density functional theory (DFT) calculations. 3D-QSAR model had good predictive ability (R² = 0.9516, Q² = 0.5989, RMSE = 0.82, and Pearson's r = 0.845). The results of the pharmacophore analysis showed that the critical features for anticancer activity are an aromatic ring, hydrophobic, and hydrogen bond acceptor. According to the ADMET evaluation, compounds 1, 7, 25, and 13 have the highest potential to be developed into drug-like substances; compound 1 has the best ADMET score of 6.348. The molecular docking study of the ligands with ER-α (PDB ID: 3ERT) demonstrated that ligands 7, 1 and 25 exhibit significantly better binding affinities (-11.98, -11.48, and -11.04 kcal/mol, respectively) than 4-hydroxytamoxifen (-8.26 kcal/mol). The MD simulations showed that ligand 7 formed a considerably more compact and stable ER-α complex through consistent hydrogen bond interactions for the duration of the simulation (100 ns). The DFT analyses indicated ligand 7 had kinetic stability and significantly better electronic properties than the other ligands studied. ligand 7 for the development of breast cancer drugs that target ER-α.
No takes yet. Share an insight, caveat, or question.
Garhewal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: